Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
14NOV

LSIMF sends £80m+ to four regional sites

3 min read
18:53UTC

Barnstaple, Birmingham, Haverhill, Hengoed. Every Life Sciences Innovative Manufacturing Fund cheque this round landed outside the Golden Triangle, and the geography is the whole point.

TechnologyDeveloping
Key takeaway

LSIMF's regional spread turns life sciences capex into a deliberate tool of industrial geography rather than a research grant.

The Life Sciences Innovative Manufacturing Fund (LSIMF) allocated over £80m to four UK sites on 14 April 2026: Accord Healthcare in Barnstaple received over £45m for generic and bipolar-medicine manufacturing; the University of Birmingham's Precision Health Technologies Accelerator received £10m for cell and gene therapy and mRNA biomanufacturing; Codis in Haverhill received funding for a spray-drying facility for cancer and neurodegenerative therapies, creating 29 new jobs; and Norgine in Hengoed, South Wales, received over £20m for pharmaceutical facility expansion.⁠1

LSIMF sits inside the UK's broader life sciences industrial strategy and is administered by DSIT. Its remit is manufacturing capex rather than research grants, which matters because Britain's historic problem is not inventing medicines but making them at commercial scale. Accord's Barnstaple facility alone covers 9% of NHS prescriptions by volume; losing it offshore would be a sovereignty problem before it became an employment one. The fund deliberately steers capex away from the research-heavy Oxford-Cambridge-London corridor toward regions with slower wage inflation and available industrial land.

DSIT designed the geographic pattern deliberately. Grant award counts across UK innovation funding are at a 10-year low even as average grant size rises; the policy response has been to consolidate fewer, larger cheques into regional sites that would not otherwise attract private pharmaceutical capex. Devon, Suffolk, Birmingham and South Wales each get a named beneficiary and a dated announcement. Cumulative UK life sciences investment in 2026 stands at £600m; DSIT is targeting £1bn by summer, leaving roughly £400m still to be announced before July with the Golden Triangle deliberately excluded from the remaining pool.

For operators in regional pharma manufacturing, the signal is that LSIMF rounds are now a forecastable policy pipeline rather than a one-off window. For Golden-Triangle biotech, the absence of any London, Oxford or Cambridge cheque this week is itself a commissioning note.

Deep Analysis

In plain English

The government has given over £80m to four pharmaceutical factories in Devon, Birmingham, Suffolk, and South Wales. These are places that usually miss out when big innovation grants are handed out, which tend to cluster around London, Oxford, and Cambridge. Accord Healthcare in Barnstaple makes medicines that cover nearly one in ten NHS prescriptions, meaning millions of people rely on it directly. The grants are designed to modernise the factories and create jobs outside the south-east.

Deep Analysis
Root Causes

NHS procurement of generic medicines is dominated by import from Indian and Eastern European manufacturers; Accord Healthcare's Barnstaple facility covers 9% of NHS prescriptions by volume, but the supply chain remains exposed to logistics disruption because no strategic reserve requirement exists in UK pharmaceutical regulation, unlike the 90-day mandatory reserves France and Germany operate under EU Directive 2001/83/EC.

The UK's post-Brexit exclusion from the EMA's pan-European medicines stockpile system (ECEI) removed a buffer that previously smoothed regional supply shocks; the LSIMF is partly a domestic resilience response to that regulatory gap.

What could happen next?
  • Consequence

    If Codis in Haverhill hires all 29 announced jobs within 12 months and files for a follow-on LSIMF grant in the next funding round, it will become the benchmark case for whether small-site LSIMF investment produces additionality or simply supports existing operators.

    Short term · 0.65
  • Risk

    The £400m still to be announced before July 2026 under the £1bn LSIMF target, if concentrated in the three remaining sites, creates a planning and construction queue that will collide with UK construction capacity shortages, likely slipping at least two facilities by 12-18 months.

    Medium term · 0.6
  • Opportunity

    Norgine's £20m Hengoed expansion positions South Wales as a candidate for the next round of LSIMF allocations targeting active pharmaceutical ingredient (API) production, which the UK currently imports at 95% dependency on Asian suppliers.

    Medium term · 0.5
First Reported In

Update #2 · Britain's innovation pipe leaks at both ends

DSIT· 22 Apr 2026
Read original →
Causes and effects
This Event
LSIMF sends £80m+ to four regional sites
The LSIMF allocation sets a deliberate precedent for non-Golden Triangle life sciences capital, with cumulative 2026 UK investment now at £600m against a £1bn summer target.
Different Perspectives
Association of Investment Companies (Richard Stone)
Association of Investment Companies (Richard Stone)
The trust industry body criticised the Budget for leaving Venture Capital Trust relief at 20%. It had lobbied for the 30% rate to return.
Tax Justice UK
Tax Justice UK
The campaign group opposed the 10% founders' rate as a giveaway to a small group of wealthy owners. It said the BADR cut should have gone further, to abolition.
techUK
techUK
The trade body set the new relief against the BADR cut, which halves the most a seller can save to £30,000. It says the Budget takes back with BADR part of what it gives founders.
Startup Coalition
Startup Coalition
The founder lobby group welcomed the Budget package for startups. It treats the new relief as the strongest government support for founders in years.
HM Treasury
HM Treasury
The Treasury created a 10% founders' relief on up to £10m of lifetime gains and expects about 600 people a year to use it. It says the relief rewards founders behind the UK's fastest-growing companies.
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.